Medicare GLP-1 Bridge Program Explained

Updated April 20, 2026

Starting July 1, 2026, Medicare will cover Wegovy and Zepbound specifically for weight management at a $50/month copay. This is the first time in Medicare's history that Part D plans will pay for obesity medication that isn't tied to a diabetes diagnosis. It's called the Medicare GLP-1 Bridge Program, and it's designed as a transitional benefit while CMS works on a more permanent Part D formulary expansion in January 2027.

If you're on Medicare and you've been eyeing Wegovy or Zepbound for weight loss, this is the breakthrough you've been waiting for. Here's what you need to know.

What the Bridge Program Covers

Two medications qualify for Bridge coverage:

• Wegovy (both injection and oral pill) — semaglutide, manufactured by Novo Nordisk
• Zepbound — tirzepatide, manufactured by Eli Lilly

Both are FDA-approved for chronic weight management, which is why they're the Bridge's targets. Mounjaro (diabetes-approved tirzepatide) is not part of the Bridge because it's already covered under standard Part D for diabetes. Foundayo is not included because it's too new to have a full CMS pricing negotiation history. Expect Foundayo to be added to the Bridge or its successor program sometime in 2027.

The Cost: $50/Month Flat

The Bridge program sets a $50 flat monthly copay for qualifying beneficiaries. Compared to:

• Retail Wegovy ($1,350) — Bridge saves you $1,300/month
• Retail Zepbound ($1,086) — Bridge saves you $1,036/month
• TrumpRx self-pay Wegovy pill ($149) — Bridge beats it by $99/month
• TrumpRx self-pay Zepbound ($299) — Bridge beats it by $249/month

The Bridge is cheaper than every existing self-pay alternative. For Medicare beneficiaries who qualify, nothing else will be competitive.

Eligibility

To qualify for Bridge coverage, you must:

• Be enrolled in Medicare Part D (standalone or as part of Medicare Advantage with Part D)
• Have a BMI threshold: typically BMI ≥ 30, or BMI ≥ 27 with at least one weight-related comorbidity (hypertension, prediabetes, sleep apnea, etc.)
• Have a prescription from a Medicare-enrolled provider specifically for weight management
• Not have a medical contraindication to the drug class

The BMI threshold and comorbidity rules mirror the FDA-approved indications for Wegovy and Zepbound. If your doctor can document that you meet those criteria, you should qualify.

How to Enroll

Good news: you don't have to enroll in a separate program. Bridge coverage is automatic for qualifying beneficiaries through your existing Part D plan starting July 1, 2026. Your steps:

1. Confirm your Part D plan is participating. Most standalone Part D plans and Medicare Advantage plans with Part D are. Your plan will notify you by mail in May or June 2026 if they're participating.
2. See your prescriber. Get a prescription for Wegovy or Zepbound specifically for weight management. Your prescriber will document BMI and any comorbidities.
3. Fill the prescription starting July 1, 2026. Prior authorization may be required depending on your plan. The $50 copay applies at the pharmacy or through mail-order.

Timeline: Bridge → Full Part D Expansion

The Bridge is explicitly a transitional program. The longer-term framework is the CMS BALANCE Model, which expands to Part D formularies in January 2027. After that, expect:

• Full Part D inclusion of Wegovy, Zepbound, and eventually Foundayo on standard formularies.
• Copay structure likely to persist around $50/month, possibly with some plans offering lower via competitive pricing.
• Mandatory inclusion requirements removing the "plan doesn't cover it" scenario that currently affects commercial insurance patients.

Translation: if you can wait until July 2026, you'll get $50/month. If you can wait until January 2027, that $50/month gets baked into standard Part D and should persist indefinitely.

What If You Need a GLP-1 Before July 2026?

The Bridge doesn't help you today. Your options between now and July 1, 2026:

1. Self-pay via TrumpRx

TrumpRx is the best available self-pay pricing for Medicare beneficiaries:

• Wegovy pill: $149/month
• Wegovy injection: $199/month
• Zepbound: $299/month

For a 3-month bridge to the Bridge, total out-of-pocket through June 2026: Wegovy pill = $447, Wegovy injection = $597, Zepbound = $897. After July 1, you switch to $50/month.

2. Novo Nordisk PAP or Lilly Cares

Both accept Medicare beneficiaries. Income threshold is roughly 400% of federal poverty level. If you qualify, the medication is free. Application takes 4–8 weeks, so start now.

3. Medicare Advantage preemptive coverage

Some Medicare Advantage plans are rolling out weight-loss GLP-1 coverage ahead of the federal Bridge. If you're in Medicare Advantage, call member services directly to ask.

What the Bridge Does NOT Do

• Doesn't cover Mounjaro for weight loss (Mounjaro is FDA-approved for diabetes; use Part D's standard diabetes coverage).
• Doesn't cover Ozempic for weight loss (Ozempic isn't FDA-approved for weight management; use Part D's cardiovascular/diabetes coverage instead).
• Doesn't waive prior authorization — your plan may still require BMI documentation.
• Doesn't help if you're uninsured — this is a Medicare Part D benefit only.
• Doesn't stack with manufacturer savings cards — savings cards already don't work with Medicare.

Bottom Line

The Medicare GLP-1 Bridge is the biggest cost change for Medicare beneficiaries seeking GLP-1s in 2026. If you're on Medicare and your doctor has recommended Wegovy or Zepbound for weight management, wait until July 1 if you can — $50/month beats every alternative. If you need access sooner, TrumpRx self-pay through June is your bridge, and the NovoCare/Lilly Cares PAPs are worth applying to in parallel.